Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates

Journal of Oral and Maxillofacial Surgery

Volumn 68, Issue 9, 2010, Pages 2241-2247

  Lazarovici, Towy Sorel ^a   Mesilaty Gross, Shlomit ^a   Vered, Iris ^a,b   Pariente, Clara ^a   Kanety, Hannah ^a   Givol, Navot ^a   Yahalom, Ran ^a   Taicher, Shlomo ^a   Yarom, Noam ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMOXICILLIN; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; CLODRONIC ACID; COLLAGEN TYPE 1; DOXYCYCLINE; PAMIDRONIC ACID; PARATHYROID HORMONE; RISEDRONIC ACID; ZOLEDRONIC ACID; ALPL PROTEIN, HUMAN; BONE DENSITY CONSERVATION AGENT; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; PEPTIDE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BLOOD SAMPLING; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DENTAL SURGERY; DISEASE COURSE; FEMALE; HUMAN; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; MALE; ORAL SURGERY; PARATHYROID HORMONE BLOOD LEVEL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; BLOOD; BONE NECROSIS; CHEMICALLY INDUCED DISORDER; CHI SQUARE DISTRIBUTION; INTRAVENOUS DRUG ADMINISTRATION; JAW DISEASE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; RISK; RISK ASSESSMENT; STATISTICAL MODEL;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; CHI-SQUARE DISTRIBUTION; COLLAGEN TYPE I; DIPHOSPHONATES; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; JAW DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; ORAL SURGICAL PROCEDURES; OSTEONECROSIS; PARATHYROID HORMONE; PEPTIDES; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; YOUNG ADULT;

EID: 77956621871     PISSN: 02782391     EISSN: 15315053     Source Type: Journal    
DOI: 10.1016/j.joms.2010.05.043     Document Type: Article

References (45)

1. Kanis JA, Gertz BJ, Singer F, et al: Rationale for the use of alendronate in osteoporosis. Osteoporos Int 5:1, 1995
2. Glover D, Lipton A, Keller A, et al: Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. Cancer 74:2949, 1994
3. Body JJ, Lortholary A, Romieu G, et al: A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 14:1557, 1999
4. Rogers MJ, Watts DJ, Russell R: Overview of bisphosphonates. Cancer 80:1652, 1997 (Suppl)
5. Boissier S, Ferreras M, Peyruchaud O, et al: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60:2949, 2000
6. Wang J, Goodger NM, Pogrel MA: Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61:1104, 2003
7. Marx RE: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 61:1115, 2003
8. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al: Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62:527, 2004
9. Marx RE, Sawatari Y, Fortin M, et al: Bisphosphonate-induced exposed bone (osteonecrosis/osteoporosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567, 2005
10. Migliorati CA, Casiglia J, Epstein J, et al: Managing the care of patients with bisphosphonate-associated osteonecrosis: An American Academy of Oral Medicine position paper. J Am Dent Assoc 136:1658, 2005
11. Mavrokokki T, Cheng A, Stein B, et al: Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65:415, 2007
12. Yarom N, Yahalom R, Shoshani Y, et al: Osteonecrosis of the jaw induced by orally administered bisphosphonates: Incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 18:1363, 2007
13. Lazarovici TS, Yahalom R, Taicher S, et al: Bisphosphonaterelated osteonecrosis of the jaws: A single-center study of 101 patients. J Oral Maxillofac Surg 67:850, 2009
14. Lazarovici TS, Yahalom R, Taicher S, et al: Bisphosphonaterelated osteonecrosis of the jaws associated with dental implants. J Oral Maxillofac Surg 68:790, 2010
15. Hellstein JW, Marek CL: Bisphosphonate osteochemonecrosis (bis-phossy jaw): Is this phossy jaw of the 21st century? J Oral Maxillofac Surg 63:682, 2005
16. Russell RG, Watts NB, Ebetino FH, et al: Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733, 2008
17. Oteri AG, Nastro E: Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells. Hematol Oncol 25:164, 2007
18. Guerrero R, Martin D, Diaz DEM, et al: New biochemical markers of bone resorption derived from collagen breakdown in the study of postmenopausal osteoporosis. Osteoporos Int 6:297, 1996
19. Garnero P, Shih WJ, Gineyts E, et al: Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693, 1994
20. Bergmann P, Body JJ, Boonen S, et al: Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: A consensus document of the Belgian Bone Club. Int J Clin Pract 63:19, 2009
21. Szulc P, Delmas PD: Biochemical markers of bone turnover: Potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int 19:1683, 2008
22. Reginster JY, Henrotin Y, Christiansen C, et al: Bone resorption in post-menopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type I. Calcif Tissue Int 69:130, 2001
23. Bjarnason NH, Christiansen C: Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women. Bone 26:561, 2000
24. Rosen CJ, Chesnut CH III, Mallinak NJ: The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 82:1904, 1997
25. Rosen HN, Moses AC, Garber J, et al: Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 66:100, 2000
26. Briot K, Trémollières F, Thomas T, et al: How long should patients take medications for postmenopausal osteoporosis? Joint Bone Spine 74:24, 2007
27. Potts JT: Parathyroid hormone: Past and present. J Endocrinol 187:311, 2005
28. Weisman SM, Matkovic V: Potential use of biochemical markers of bone turnover for assessing the effect of calcium supplementation and predicting fracture risk. Clin Ther 27:299, 2005
29. Abu-Id MH, Warnke PH, Gottschalk J, et al: Bis-phossy jaws - High and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Craniomaxillofac Surg 36:95, 2008
30. Marx RE, Cillo JE, Ulloa JJ: Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65:2397, 2007
31. Kunchur R, Need A, Hughes T, et al: Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg 67:1167, 2009
32. American Association of Oral and Maxillofacial Surgeons: Position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65:369, 2007
33. Rosenquist C, Fledelius C, Christgau S, et al: Serum CrossLaps One Step ELISA: First application of monoclonal antibodies for measurement in serum of bone-related degradation products from Cterminal telopeptides of type I collagen. Clin Chem 44:2281, 1998
34. Gomez B Jr, Ardakani S, Ju J, et al: Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 41:1560, 1995
35. Godber IM, Parker CR, Lawson N, et al: Comparison of intact and "whole molecule" parathyroid hormone assays in patients with histologically confirmed post-renal transplant osteodystrophy. Ann Clin Biochem 39:314, 2002
36. Martínez J, Olmos JM, Hernández JL, et al: Bone turnover markers in Spanish postmenopausal women: The Camargo cohort study. Clin Chim Acta 409:70, 2009
37. Trento LK, Pietropolli A, Ticconi C, et al: Role of type I collagen C telopeptide, bone-specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women. J Obstet Gynaecol Res 35:152, 2009
38. Khosla S, Burr D, Cauley J, et al: Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. American Society for Bone and Mineral Research Task Force on Osteonecrosis of the jaw. J Oral Maxillofac Surg 66:1320, 2008
39. Bagan JV, Jiménez Y, Gómez D, et al: Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates. Oral Oncol 44:1088, 2008
40. Lehrer S, Montazem A, Ramanathan L, et al: Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 106:389, 2008
41. Kwon YD, Kim DY, Ohe JY, et al: Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67:2644, 2009
42. Ardine M, Generali D, Donadio M, et al: Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw? Ann Oncol 17:1336, 2006
43. Lo JC, O'Ryan FS, Gordon NP, et al: Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure: Predicting risk of osteonecrosis of the jaw with oral bisphosphonate Exposure (PROBE) Investigators. J Oral Maxillofac Surg 68:243, 2010
44. Boonyapakorn T, Schirmer I, Reichart PA, et al: Bisphosphonate- induced osteonecrosis of the jaws: Prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44:857, 2008
45. Sedghizadeh PP, Stanley K, Caligiuri M, et al: Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw. J Am Dent Assoc 140:61, 2009